# Clazakizumab vs. Placebo - COVID-19 Infection

> **NCT04494724** · PHASE2 · UNKNOWN · sponsor: **The Methodist Hospital Research Institute** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** Clazakizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04494724
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-13
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494724, "Clazakizumab vs. Placebo - COVID-19 Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04494724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*